vTv Therapeutics Inc.
Business
vTv Therapeutics Inc. is a late-stage biopharmaceutical company developing orally administered therapies for metabolic and inflammatory diseases. Its lead candidate, cadisegliatin (TTP399), a liver-selective glucokinase activator, is in Phase 3 clinical trials for type 1 diabetes as an adjunctive therapy to insulin. The company also maintains a pipeline of earlier-stage programs including a GLP-1 receptor agonist (TTP273), RAGE antagonist (TTP-RA), PPAR-delta agonist (HPP593), and Nrf2/Bach1 modulators, with select programs partnered or in preclinical development. The company operates as a single reportable segment focused on drug development without geographic or business-line segmentation.
Summary from 10-K filed 2026-03-10
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 0 | 2 | 4 | |
| Research and development | 18 | 12 | 14 | 12 | 13 | |
| General and administrative | 15 | 14 | 12 | 12 | 12 | |
| Total operating expenses | 33 | 25 | 26 | 25 | 26 | |
| Operating loss | −33 | −24 | −26 | −23 | −22 | |
| Interest income | 2 | 2 | 472,000 | 352,000 | 1,000 | |
| Interest expense | −6,000 | 0 | −13,000 | — | — | |
| Loss before income taxes and noncontrolling interest | −31 | −23 | −26 | −25 | −18 | |
| Income tax provision | 0 | 100,000 | 0 | 200,000 | 100,000 | |
| Net loss before noncontrolling interest | −31 | −23 | −26 | −25 | −18 | |
| Net loss attributable to noncontrolling interest | −4 | −4 | −6 | −6 | −5 | |
| Net loss attributable to vTv Therapeutics Inc. | −27 | −18 | −20 | −19 | −13 | |
| Net loss attributable to vTv Therapeutics Inc. common shareholders | −27 | −18 | −20 | −19 | −13 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 89 | 37 | 9 | 12 | 13 | |
| Prepaid expenses | 743,000 | 1 | — | — | — | |
| Other current assets | 218,000 | 175,000 | — | — | — | |
| Total current assets | 90 | 38 | 11 | 27 | 16 | |
| Other assets | 6,000 | 153,000 | — | — | — | |
| Total assets | 90 | 38 | 11 | 33 | 25 | |
| Accounts payable and accrued expenses | 7 | 5 | 10 | 7 | 8 | |
| Current portion of operating lease liabilities | 0 | 169,000 | 169,000 | 154,000 | 184,000 | |
| Total current liabilities | 7 | 5 | 11 | 8 | 8 | |
| Contract liabilities, net of current portion | 19 | 19 | 19 | 19 | 0 | |
| Total liabilities | 25 | 24 | 30 | 27 | 10 | |
| Commitments and contingencies | — | — | — | — | — | |
| Additional paid-in capital | 391 | 312 | 256 | 255 | 238 | |
| Accumulated deficit | −327 | −300 | −281 | −266 | −249 | |
| Total stockholders equity attributable to vTv Therapeutics Inc. | 64 | 12 | −25 | −11 | −10 | |
| Noncontrolling interest | 0 | 2 | 0 | — | — | |
| Total stockholders equity | 64 | 14 | −25 | −11 | −10 | |
| Total liabilities, redeemable noncontrolling interest and stockholders equity | 90 | 38 | 11 | 33 | 25 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 16,000 | 89,000 | 90,000 | 100,000 | 100,000 | |
| Loss on disposal of property and equipment | 6,000 | 0 | 0 | — | — | |
| Loss from G42 Promissory Note early redemption | 0 | 0 | 313,000 | 0 | 0 | |
| Non-cash interest income | 0 | 0 | −100,000 | −352,000 | 0 | |
| Share-based compensation expense | 4 | 3 | 2 | 1 | 2 | |
| Realized gain on sale of investment in Reneo Pharmaceuticals, Inc. | 0 | 0 | −3 | 0 | 0 | |
| Impairment of investments in Anteris Bio, Inc. | 0 | 0 | 4 | 0 | 0 | |
| Prepaid expenses | 449,000 | −216,000 | 2 | −403,000 | −839,000 | |
| Other current assets | −43,000 | 60,000 | −37,000 | — | — | |
| Other assets | 125,000 | 119,000 | 105,000 | — | — | |
| Accounts payable and accrued expenses | 2 | −5 | 3 | −856,000 | 2 | |
| Contract liabilities | 0 | −17,000 | 0 | 7 | −1 | |
| Other liabilities | −169,000 | −169,000 | −154,000 | 0 | −50,000 | |
| Net cash used in operating activities | −25 | −25 | −19 | −16 | −19 | |
| Proceed from sale of investments in Reneo Pharmaceuticals, Inc. | 0 | 0 | 4 | 0 | 0 | |
| Net cash provided by (used in) investing activities | 0 | 0 | 4 | −21,000 | 0 | |
| Proceeds from sale of Class A common stock, pre-funded and common warrants, net of offering costs | 77 | 0 | 0 | — | — | |
| Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs | 0 | 50 | 0 | 0 | 0 | |
| Proceeds from issuance of Class A common stock, net of offering costs | 0 | 2 | 0 | 0 | 27 | |
| Proceeds from sale of Class A common stock to collaboration partner, net of offering costs | 0 | 0 | 12 | 5 | 0 | |
| Proceeds from the exercise of stock options | 16,000 | 0 | 0 | 0 | 47,000 | |
| Taxes paid related to net share settlement of equity awards | −51,000 | 0 | 0 | — | — | |
| Proceeds from debt issuance | 392,000 | 0 | 566,000 | 776,000 | 887,000 | |
| Repayment of notes payable | −392,000 | −191,000 | −599,000 | −808,000 | −715,000 | |
| Net cash provided by financing activities | 77 | 53 | 12 | 15 | 27 | |
| Net increase (decrease) in cash, cash equivalents | 52 | 27 | −3 | −1 | 8 | |
| Cash paid for interest | 6,000 | 2,000 | 14,000 | 15,000 | 11,000 | |
| Cash paid for income taxes | 0 | 100,000 | 0 | 200,000 | 115,000 | |
| Reclassification of noncontrolling interest to additional paid-in capital | 2 | 5 | 0 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is vTv Therapeutics Inc.'s CIK number?
vTv Therapeutics Inc.'s SEC CIK number is 0001641489 (1641489). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find vTv Therapeutics Inc.'s SEC filings?
All of vTv Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did vTv Therapeutics Inc. last report earnings?
vTv Therapeutics Inc. (VTVT) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001641489-26-000019). This is vTv Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is vTv Therapeutics Inc.'s most recent earnings 8-K?
vTv Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001641489-26-000019. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View vTv Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →